Novavax COVID-19 Vaccine Nuvaxovid(TM) Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
By asianet
–Upon authorization, Nuvaxovid(TM) would be the first protein-based option for adolescents aged 12 through 17 in Europe –Nuvaxovid(TM) demonstrated 80% efficacy and was generally well-tolerated in adolescents Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid(TM) (NVX-CoV2373) COVID-19 vaccine has been … Continued